PT-141 and alcohol have been studied together, and Vyleesi's label does not set a specific alcohol restriction. But the evidence comes from just 24 healthy adults using a nasal preparation. It does not establish a safe drinking amount for every person or prescription.
PT-141 is another name for bremelanotide, the medicine in Vyleesi. The clearest separate warning concerns oral naltrexone, a medicine used for alcohol or opioid addiction. Vyleesi can reduce how much of it reaches the blood.
PT-141 and alcohol: what the study tested
The Vyleesi prescribing information on DailyMed reads “Revised: 3/2024.” Its alcohol section describes a nasal-spray experiment, rather than a test of the marketed injection.
The 2017 study by Clayton and colleagues in Clinical Therapeutics enrolled 12 men and 12 women. Everyone received three combinations on different days: bremelanotide with alcohol, bremelanotide with a placebo drink, and alcohol with a placebo spray. Placebo means an inactive comparison treatment.
Doses were given on days 1, 4, and 7: on two of those days the spray held 20 mg of bremelanotide, and on the third it was a placebo. The alcohol amount was 0.6 grams per kilogram of body weight. The spray followed the drink by 10 minutes, and participants had fasted overnight.
For a 70-kilogram person, the label equates that alcohol amount to about three beers, glasses of wine, or shots at specified sizes and strengths. That describes the experiment. It is not a suggested amount to drink.
The label reports these findings:
| Question | What happened in the study |
|---|---|
| Did alcohol change bremelanotide levels in blood? | It did not change how those levels rose and fell. |
| Were blood-pressure drops on standing more frequent? | Their frequency was comparable with the combination and alcohol alone. |
| Did flushing increase? | More than with alcohol alone, but similarly to bremelanotide alone. Flushing means warmth or redness. |
| Did headaches increase? | More than with bremelanotide alone, but similarly to alcohol alone. |
All 24 participants completed the study, and nobody stopped because of side effects.
What those reassuring results cannot settle
This was a seven-day experiment in healthy volunteers. It cannot establish the effects of heavier drinking, repeated use over months, heart disease, or every combination of medicines.
The label says the nasal study dose produced an average peak blood level 2.5 times that of Vyleesi. FDA's clinical pharmacology reviewer judged the design sufficient to detect a drug-level interaction between the two. It does not make the two preparations interchangeable or provide a conversion between them.
The FDA's detailed review, pages 205–207, adds useful context. Across the study treatments, average blood-pressure changes were small, and heart rate increased over the observation period. Those findings belong to this alcohol experiment, separate from Vyleesi's usual pressure-and-pulse warning.
One man fainted for about 15 seconds after the combination. His blood sugar had dropped to 51 mg/dL, which reviewers linked to the orange-juice drink taken after an overnight fast, a pattern he showed in all three study periods, and they called it an isolated occurrence. No events were classified as serious. The overall findings therefore do not mean that nobody experienced an unpleasant reaction.
Oral naltrexone changes the conversation
The naltrexone warning is more direct than the alcohol findings. The concern is systemic exposure, meaning how much naltrexone reaches the bloodstream. Vyleesi can reduce that amount after naltrexone is taken by mouth.
The label's highlights, referring to Section 7.2, say Vyleesi:
may significantly decrease the systemic exposure of orally-administered naltrexone; avoid use with orally administered naltrexone-containing products intended to treat alcohol or opioid addiction.
The full section explains that naltrexone treatment failure can have serious consequences. This is a warning about interference with another treatment, even when someone is not drinking.
Bremelanotide may slow gastric emptying, meaning how quickly contents leave the stomach. That can change absorption of oral medicines. The Vyleesi label walkthrough explains the wider medication-interaction section.
For a person receiving addiction treatment, the clinician reviewing PT-141 needs the exact medicine and how it is given. That review belongs alongside existing care; the alcohol study is not a reason to interrupt naltrexone treatment.
Blood pressure and nausea still matter
Vyleesi's separate warning describes a temporary blood-pressure rise and slower pulse after each dose. They usually return to starting levels within 12 hours. The label rules out Vyleesi with uncontrolled high blood pressure or known heart or blood-vessel disease.
That warning does not disappear because the alcohol study was generally reassuring. The PT-141 blood-pressure guide explains why recent readings and heart history matter.
Feeling sick is another practical concern. In the two RECONNECT trials, about 2 in 5 treated women reported nausea: 40.0%, versus 1.3% with placebo. Those figures come from the full 2019 report by Kingsberg and colleagues in Obstetrics & Gynecology. They describe the injection trials, rather than the chance of nausea after combining PT-141 with alcohol.
The PT-141 side-effects guide covers the broader safety picture, and PT-141 myths grades the claims people repeat about it. Persistent or severe nausea changes the prescriber's assessment of whether treatment remains suitable.
Drinking and low desire are separate questions
Vyleesi's indication, meaning its labeled use, covers certain women before menopause with distressing low sexual desire. The problem must have developed after a period without desire problems and occur across situations or partners.
Section 1 excludes low desire explained by another health condition, relationship problems, or a medication or drug substance. The label also excludes men, women after menopause, and sexual-performance enhancement from its indicated uses.
That makes the pattern of drinking relevant beyond an interaction check. A provider considers what is causing low desire, not simply whether two substances have been tested together.
The product and prescription still matter
PT-141 prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded means prepared by a pharmacy for an individual prescription. Vyleesi's findings cannot establish identical effects for another finished preparation. The FDA's compounding explanation describes that distinction.
As of October 29, 2026, the day this article was written, an FDA warning letter dated August 24, 2026 names an online seller's PT-141 among unapproved new drugs. A prescribed route adds a reviewing clinician, an identifiable licensed dispensing pharmacy, and a contact for problems.
A licensed provider may still prescribe — that decision is between you and your doctor.
What the review needs to know
The useful details are the drinking pattern, all current medicines, recent blood-pressure readings, heart history, and the reason for considering PT-141. Oral naltrexone deserves particular attention, including when someone is not currently drinking.
The provider sets any prescribed amount, timing, and follow-up plan. How to use PT-141 covers the separate timing questions; the alcohol experiment does not establish a waiting interval before or after a prescription.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
